[1]郑元建,韩慧,朱月莹.玻璃体内注射雷珠单抗与康柏西普治疗特发性脉络膜新生血管的临床疗效对比[J].眼科新进展,2020,40(2):177-179.[doi:10.13389/j.cnki.rao.2020.0042]
　ZHENG Yuanjian,HAN Hui,ZHU Yueying.Comparative study on clinical efficacy between intravitreal injection of Ranibizumab and Conbercept in treatment of idiopathic choroidal neovascularization[J].Recent Advances in Ophthalmology,2020,40(2):177-179.[doi:10.13389/j.cnki.rao.2020.0042]
点击复制

玻璃体内注射雷珠单抗与康柏西普治疗特发性脉络膜新生血管的临床疗效对比/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
40卷
期数:
2020年2期
页码:
177-179
栏目:
应用研究
出版日期:
2020-02-05

文章信息/Info

Title:
Comparative study on clinical efficacy between intravitreal injection of Ranibizumab and Conbercept in treatment of idiopathic choroidal neovascularization
作者:
郑元建; 韩慧; 朱月莹
516200　广东省惠州市，惠州市第六人民医院眼科
Author(s):
ZHENG Yuanjian; HAN Hui; ZHU Yueying
Department of Ophthalmology，the Sixth People’s Hospital of Huizhou，Huizhou 516200，Guangdong Province，China
关键词:
特发性脉络膜新生血管; 玻璃体内注射; 雷珠单抗; 康柏西普
Keywords:
idiopathic choroidal neovascularization; intravitreal injection; Ranibizumab; Conbercept
分类号:
R774.1
DOI:
10.13389/j.cnki.rao.2020.0042
文献标志码:
A
摘要:
目的　对比分析玻璃体内注射雷珠单抗与康柏西普治疗特发性脉络膜新生血管（idiopathic choroidal neovascularization，ICNV）的临床疗效。方法　选取2016年1月至2018年6月我院收治的ICNV患者90例（90眼），依据患者治疗情况分为雷珠单抗组及康柏西普组，每组患者各45例（45眼）。康柏西普组患者采取玻璃体内注射康柏西普0.05 mL进行治疗，雷珠单抗组采取玻璃体内注射雷珠单抗0.05 mL进行治疗。对两组患者治疗前及治疗3个月、6个月后最佳矫正视力、黄斑中心凹厚度以及治疗结束后不良反应发生率进行对比分析。结果　康柏西普组治疗前及治疗3个月、6个月后最佳矫正视力、黄斑中心凹厚度分别为0.34±0.10、0.60±0.25、0.80±0.20和（374.10±1.18）μm、（289.02±1.30）μm、（215.06±1.20）μm；雷珠单抗组分别为0.33±0.11、0.57±0.24、0.78±0.23和（373.55±1.15）μm、（288.97±1.23）μm、（215.11±1.17）μm。治疗前两组患者最佳矫正视力、黄斑中心凹厚度比较，差异均无统计学意义（均为P＞0.05）；治疗3个月、6个月后最佳矫正视力均高于治疗前，黄斑中心凹厚度均低于治疗前，差异均有统计学意义（均为P＜0.05）。治疗不同时间后，康柏西普组患者最佳矫正视力、黄斑中心凹厚度与雷珠单抗组相差均不大（均为P＞0.05）。治疗结束后康柏西普组不良反应发生率为11.11%，雷珠单抗组为8.89%，两组不良反应发生率差异无统计学意义（χ2=0.274，P＞0.05）。结论　玻璃体内注射雷珠单抗与康柏西普治疗ICNV后，患者最佳矫正视力均提高，黄斑中心凹厚度变薄，且不良反应发生率降低。
Abstract:
Objective　To compare the clinical efficacy between intravitreal injection of Ranibizumab and Conbercept in the treatment of idiopathic choroidal neovascularization (ICNV).Methods　Totally 90 patients (90 eyes) with ICNV who received intravitreal injection of Ranibizumab or Conbercept in our hospital from January 2016 to June 2018,were randomly divided into Ranibizumab group and Conbercept group,45 patients (45 eyes) in each group.Patients in Conbercept group received intravitreal injection of 0.05 mL Conbercept,and those in Ranibizumab group received intravitreal injection of 0.05 mL Ranibizumab.Best corrected visual acuity (BCVA) and central foveal thickness before treatment,3 months and 6 months after treatment,and incidence of adverse reactions after treatment were compared between the two groups.Results　Before treatment,3 months and 6 months after treatment,BCVA were 0.34±0.10,0.60±0.25 and 0.80±0.20,and central foveal thickness were (374.10±1.18)μm,(289.02±1.30)μm and (215.06±1.20)μm for patients in Conbercept group;BCVA were 0.33±0.11,0.57±0.24 and 0.78±0.23,and central foveal thickness were (373.55±1.15)μm,(288.97±1.23)μm and (215.11±1.17)μm for patients in Ranibizumab group.There were no statistical differences in BCVA or central foveal thickness between two groups before treatment (all P>0.05).At 3 months and 6 months after treatment,BCVA were higher than those before treatment,and central foveal thickness were lower than those before treatment (all P<0.05).At different time points after treatment,the BCVA and central foveal thickness in Conbercept group were not significantly different from those in Ranibizumab group (all P>0.05).After treatment,the incidence of adverse reactions was 11.11% in Conbercept group,and 8.89% in Ranibizumab group.No significant difference was found between the two groups (χ2=0.274,P＞0.05).Conclusion　After intravitreal injection of Ranibizumab and Conbercept for patients with ICNV,BCVA gets improvement,central foveal thickness becomes thinner,and the incidence of adverse reactions decreases.

参考文献/References:

［1］　JING P J，LI H W，CUI J，ZHU D M.The effect of anti-VEGF drugs in the treatment of idiopathic CNV and its effect on intraocular pressure，BCVA and mfERG［J］.Int J Ophthalmol，2018，18（2）：353-355.
［2］　VEERAPPAN M，EL-HAGE-SLEIMAN A M，TAI V，CHIU S J，WINTER K P，STINNETT S S，et al.Optical coherence tomography reflective drusen substructures predict progression to geographic atrophy in age-related macular degeneration［J］.Ophthalmology，2016，123（12）：2554-2570.
［3］　董凯，于文洲，郭超红.雷珠单抗联合中药治疗特发性息肉样脉络膜血管病变1例报告［J］.湖南中医杂志，2016，32（4）：123-124.

DONG K，YU W Z，GUO C H.Report of a case of idiopathic polypoid choroidal vasculopathy treated with ralizumab combined with traditional Chinese medicine［J］.Hunan J Tradit Chin Med，2016，32（4）：123-124.
［4］　黄延，张晓峰.玻璃体内注射抗VEGF药物治疗脉络膜新生血管疾病疗效分析［J］.临床眼科杂志，2016，24（2）：134-137.

HUANG Y，ZHANG X F.Therapeutic effect of intravitreal injection of anti-VEGF drugs on choroidal neovascularization［J］.J Clin Ophthalmol，2016，24（2）：134-137.
［5］　李婷婷，牛彤彤.光动力疗法联合玻璃体内注射雷珠单抗治疗特发性脉络膜新生血管［J］.中国继续医学教育，2015，7（2）：31-33.

LI T T，NIU T T.Photodynamic therapy combined with intravitreal injection of ranibizumab in the treatment of idiopathic choroidal neovascularization［J］.Chin Cont Med Edu，2015，7（2）：31-33.
［6］　杜伟，解正高，朱俊，陈放.玻璃体内注射雷珠单抗治疗特发性脉络膜新生血管［J］.实用临床医药杂志，2015，19（24）：50-52，79.

DU W，XIE Z G，ZHU J，CHEN F.Treatment of idiopathic choroidal neovascularization with vitreous injection of ranibizumab［J］.J Clin Med Pract，2015，19（24）：50-52，79.
［7］　叶娅，宋艳萍，闫明，黄晓莉，黄珍.玻璃体内注射雷珠单抗治疗特发性脉络膜新生血管的临床疗效观察［J］.中国激光医学杂志，2018，27（2）：143-144.

YE Y，SONG Y P，YAN M，HUANG X L，HUANG Z.Clinical efficacy of intravitreal injection of ranibizumab in the treatment of idiopathic choroidal neovascularization［J］.Chin J Laser Med，2018，27（2）：143-144.
［8］　DANIEL E，GRUNWALD J E，KIM B J，MAGUIRE M G，JAFFE G J，TOTH C A，et al.Visual and morphologic outcomes in eyes with hard exudate in the comparison of age-related macular degeneration treatments trials［J］.Ophthalmol Retin，2017，1（1）：25-33.
［9］　赵善瑶，姜涛，翟改霞，李慧，曹红，高琳.玻璃体内注射雷珠单抗治疗特发性脉络膜新生血管疗效观察［J］.眼科新进展，2016，36（6）：576-578.

ZHAO S Y，JIANG T，ZHAI G X，LI H，CAO H，GAO L.Therapeutic effect of intravitreal injection of ranibizumab in the treatment of idiopathic choroidal neovascularization［J］.Rec Adv Ophthalmol，2016，36（6）：576-578.
［10］　周波，王敏.玻璃体内注射雷珠单抗治疗脉络膜新生血管的临床分析［J］.中外医疗，2015，34（23）：104-105.

ZHOU B，WANG M.Clinical analysis of intravitreal injection of ranibizumab in the treatment of choroidal neovascularization［J］.China Foreign Med Treat，2015，34（23）：104-105.
［11］　SUN Y M，CHENG Y H，ZHANG L，SHEN F M.Therapeutic effect of ranibizumab in the treatment of type I and type Ⅱ idiopathic choroidal neovascularization［J］.Int J Ophthalmol，2015，15（7）：1210-1213.
［12］　朱锐，李圣请，曾垂钦.自拟止血化瘀方联合康柏西普治疗特发性息肉样脉络膜血管病变疗效观察［J］.临床合理用药杂志，2018，11（25）：82-83.

ZHU R，LI S Q，ZENG C Q.Therapeutic effect of Zhixue Huayu Recipe combined with Conbercept in the treatment of idiopathic polypoid choroidal vasculopathy［J］.J Clin Rat Med，2018，11（25）：82-83.
［13］　XIE Y J，DUAN G P，HU R，ZENG Q.Therapeutic effect of Compaqip on the treatment of myopic choroidal neovascularization［J］.Int J Ophthalmol，2018，18（3）：592-595.
［14］　WU Q J，QIAN F，LIU Y L，ZHAO L，CHEN X Y，MA Z Z，et al.Clinical efficacy of intravitreal injection of anti-vascular endothelial growth factor drugs in the treatment of idiopathic choroidal neovascularization［J］.Chin J Ophthalmol （Electr Ed），2015，5（1）：22-26.

相似文献/References:

[1]赵倩 金学民.Avastin联合黄斑格栅样光凝治疗糖尿病黄斑水肿的临床研究[J].眼科新进展,2013,33(2):000.
[2]田蓉 陈有信.特发性脉络膜新生血管的治疗[J].眼科新进展,2012,32(8):000.
[3]赵勇 张卯年 任兵.激素缓释系统治疗糖尿病黄斑水肿新进展[J].眼科新进展,2012,32(10):000.
[4]陆秉文 吴星伟. 苦碟子注射液联合光动力疗法与玻璃体内注射Ranibizumab治疗渗出型年龄相关性黄斑变性[J].眼科新进展,2014,34(3):268.
[5]金昱,石安娜,刘淼. 玻璃体内注射雷珠单抗（Ranibizumab）治疗视网膜静脉阻塞继发黄斑水肿[J].眼科新进展,2014,34(9):855.[doi:10.13389/j.cnki.rao.2014.0236]
[6]张聪,刘东宁,徐丽. 玻璃体内注射Lucentis治疗中心性渗出性脉络膜视网膜病变的临床疗效[J].眼科新进展,2014,34(9):864.[doi:10.13389/j.cnki.rao.2014.0239]
[7]陆秉文,吴星伟. Ranibizumab玻璃体内注射治疗病理性近视脉络膜新生血管研究进展[J].眼科新进展,2014,34(9):897.[doi:10.13389/j.cnki.rao.2014.0248]
[8]吴敏,薛黎萍,肖丽波,等.曲安奈德玻璃体内注射联合23G微创玻璃体切割术治疗脉络膜脱离型视网膜脱离的疗效分析[J].眼科新进展,2014,34(12):1144.[doi:10.13389/j.cnki.rao.2014.0317]
　WU Min,XUE Li-Ping,XIAO Li-Bo,et al.23-gauge micro-invasive vitrectomy combined with triamicinolone acetonide intravitreal injection for retinal detachment associated with choroidal detachment[J].Recent Advances in Ophthalmology,2014,34(2):1144.[doi:10.13389/j.cnki.rao.2014.0317]
[9]刘斌,杨玉霞,刘杏,等.玻璃体内注射Lucentis治疗糖尿病黄斑水肿[J].眼科新进展,2015,35(1):045.[doi:10.13389/j.cnki.rao.2015.0013]
　LIU Bin,YANG Yu-Xia,LIU Xing,et al.Intravitreal injection of Lucentis for diabetic macular edema[J].Recent Advances in Ophthalmology,2015,35(2):045.[doi:10.13389/j.cnki.rao.2015.0013]
[10]王博,吴京,马明,等. 玻璃体内注射雷珠单抗与曲安奈德治疗糖尿病黄斑水肿的疗效对比分析[J].眼科新进展,2015,35(3):246.[doi:10.13389/j.cnki.rao.2015.0066]
　WANG Bo,WU Jing,MA Ming,et al. Clinictid effect comparison of intravitreal lucentis and triamcinolone acetonide for diabetic macular edema[J].Recent Advances in Ophthalmology,2015,35(2):246.[doi:10.13389/j.cnki.rao.2015.0066]

备注/Memo

备注/Memo:
N/A
更新日期/Last Update: 2020-02-05